The Role of HER2 Status in the Biliary Tract Cancers
Abstract
Simple Summary
Abstract
1. Introduction
2. Prognostic Role of HER2 Status in BTC
3. HER2 Alterations in BTC
4. Resistance to Anti-HER2 Therapies
5. Completed and Ongoing Clinical Trials
6. Conclusions—Concluding Remarks and Future Perspectives
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kam, A.E.; Masood, A.; Shroff, R.T. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol. Hepatol. 2021, 6, 956–969. [Google Scholar] [CrossRef] [PubMed]
- Oh, D.Y.; Bang, Y.J. HER2-targeted therapies—A role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020, 17, 33–48. [Google Scholar] [CrossRef] [PubMed]
- Clements, O.; Eliahoo, J.; Kim, J.U.; Taylor-Robinson, S.D.; Khan, S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J. Hepatol. 2020, 72, 95–103. [Google Scholar] [CrossRef] [PubMed]
- Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010, 362, 1273–1281. [Google Scholar] [CrossRef][Green Version]
- Lamarca, A.; Palmer, D.H.; Wasan, H.S.; Ross, P.J.; Ma, Y.T.; Arora, A.; Falk, S.; Gillmore, R.; Wadsley, J.; Patel, K.; et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021, 22, 690–701. [Google Scholar] [CrossRef]
- Abou-Alfa, G.K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.S.; Borad, M.J.; Gallinson, D.; Murphy, A.G.; et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21, 671–684. [Google Scholar] [CrossRef]
- Javle, M.; Roychowdhury, S.; Kelley, R.K.; Sadeghi, S.; Macarulla, T.; Weiss, K.H.; Waldschmidt, D.-T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.; et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 2021, 6, 803–815. [Google Scholar] [CrossRef]
- Bahleda, R.; Meric-Bernstam, F.; Goyal, L.; Tran, B.; He, Y.; Yamamiya, I.; Benhadji, K.A.; Matos, I.; Arkenau, H.-T. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann. Oncol. 2020, 31, 1405–1412. [Google Scholar] [CrossRef]
- Goyal, L.; Meric-Bernstam, F.; Hollebecque, A.; Valle, J.W.; Morizane, C.; Karasic, T.B.; Abrams, T.A.; Furuse, J.; Kelley, R.K.; Cassier, P.A.; et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N. Engl. J. Med. 2023, 388, 228–239. [Google Scholar] [CrossRef]
- Zhu, A.X.; Macarulla, T.; Javle, M.M.; Kelley, R.K.; Lubner, S.J.; Adeva, J.; Cleary, J.M.; Catenacci, D.V.T.; Borad, M.J.; Bridgewater, J.A.; et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021, 7, 1669–1677. [Google Scholar] [CrossRef]
- van Golen, R.F.; Dekker, T.J.A. Dabrafenib plus trametinib in patients with BRAF. Lancet Oncol. 2020, 21, e515. [Google Scholar] [CrossRef] [PubMed]
- Subbiah, V.; Kreitman, R.; Wainberg, Z.; Cho, J.; Schellens, J.; Soria, J.; Wen, P.; Zielinski, C.; Cabanillas, M.; Boran, A.; et al. Dabrafenib plus trametinib in patients with BRAF. Lancet Oncol. 2020, 21, 1234–1243. [Google Scholar] [CrossRef]
- Massard, C.; Michiels, S.; Ferté, C.; Le Deley, M.-C.; Lacroix, L.; Hollebecque, A.; Verlingue, L.; Ileana, E.; Rosellini, S.; Ammari, S.; et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017, 7, 586–595. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C.; Barlesi, F.; Lolkema, M.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2020, 31, 1491–1505. [Google Scholar] [CrossRef]
- Valle, J.W.; Lamarca, A.; Goyal, L.; Barriuso, J.; Zhu, A.X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017, 7, 943–962. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Vivaldi, C.; Fornaro, L.; Ugolini, C.; Niccoli, C.; Musettini, G.; Pecora, I.; Insilla, A.C.; Salani, F.; Pasquini, G.; Catanese, S.; et al. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. Oncologist 2020, 25, 886–893. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.; Kim, R.; Kim, H.R.; Jo, H.; Kim, H.; Ha, S.Y.; Park, J.O.; Park, Y.S.; Kim, S.T. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Front. Oncol. 2022, 12, 834104. [Google Scholar] [CrossRef]
- Galdy, S.; Lamarca, A.; McNamara, M.G.; Hubner, R.A.; Cella, C.A.; Fazio, N.; Valle, J.W. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target? Cancer Metastasis Rev. 2017, 36, 141–157. [Google Scholar] [CrossRef][Green Version]
- Hiraoka, N.; Nitta, H.; Ohba, A.; Yoshida, H.; Morizane, C.; Okusaka, T.; Nara, S.; Esaki, M.; Kishi, Y.; Shimada, K. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum. Pathol. 2020, 105, 9–19. [Google Scholar] [CrossRef]
- Ata, A.; Polat, A.; Serinsöz, E.; Sungur, M.A.; Arican, A. Prognostıc value of increased HER2 expression in cancers of pancreas and biliary tree. Pathol. Oncol. Res 2015, 21, 831–838. [Google Scholar] [CrossRef]
- Rüschoff, J.; Hanna, W.; Bilous, M.; Hofmann, M.; Osamura, R.Y.; Penault-Llorca, F.; van de Vijver, M.; Viale, G. HER2 testing in gastric cancer: A practical approach. Mod. Pathol. 2012, 25, 637–650. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Nam, A.R.; Kim, J.-W.; Cha, Y.; Ha, H.; Park, J.E.; Bang, J.-H.; Jin, M.H.; Lee, K.-H.; Kim, T.-Y.; Han, S.-W.; et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 2016, 7, 58007–58021. [Google Scholar] [CrossRef] [PubMed][Green Version]
- de Bitter, T.J.J.; de Reuver, P.R.; de Savornin Lohman, E.A.; Kroeze, L.I.; Vink-Börger, M.E.; van Vliet, S.; Simmer, F.; von Rhein, D.; Jansen, E.A.M.; Verheij, J.; et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ. Precis. Oncol. 2022, 6, 83. [Google Scholar] [CrossRef] [PubMed]
- Pahuja, K.B.; Nguyen, T.T.; Jaiswal, B.S.; Prabhash, K.; Thaker, T.M.; Senger, K.; Chaudhuri, S.; Kljavin, N.M.; Antony, A.; Phalke, S.; et al. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell 2018, 34, 792–806.e5. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ayasun, R.; Sahin, I. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer. Lancet Gastroenterol. Hepatol. 2023, 8, 211. [Google Scholar] [CrossRef] [PubMed]
- Jacobi, O.; Ross, J.S.; Goshen-Lago, T.; Haddad, R.; Moore, A.; Sulkes, A.; Brenner, B.; Ben-Aharon, I. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncol. Res. Treat 2021, 44, 20–27. [Google Scholar] [CrossRef]
- Wu, X.; Yang, H.; Yu, X.; Qin, J.-J. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. Front. Pharmacol. 2022, 13, 1012552. [Google Scholar] [CrossRef]
- Bose, R.; Kavuri, S.M.; Searleman, A.C.; Shen, W.; Shen, D.; Koboldt, D.C.; Monsey, J.; Goel, N.; Aronson, A.B.; Li, S.; et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013, 3, 224–237. [Google Scholar] [CrossRef][Green Version]
- Ma, C.X.; Bose, R.; Gao, F.; Freedman, R.A.; Telli, M.L.; Kimmick, G.; Winer, E.; Naughton, M.; Goetz, M.P.; Russell, C.; et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin. Cancer Res. 2017, 23, 5687–5695. [Google Scholar] [CrossRef][Green Version]
- Meric-Bernstam, F.; Johnson, A.M.; Dumbrava, E.E.I.; Raghav, K.; Balaji, K.; Bhatt, M.; Murthy, R.K.; Rodon, J.; Piha-Paul, S.A. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin. Cancer Res. 2019, 25, 2033–2041. [Google Scholar] [CrossRef][Green Version]
- Vernieri, C.; Milano, M.; Brambilla, M.; Mennitto, A.; Maggi, C.; Cona, M.S.; Prisciandaro, M.; Fabbroni, C.; Celio, L.; Mariani, G.; et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit. Rev. Oncol. Hematol. 2019, 139, 53–66. [Google Scholar] [CrossRef] [PubMed]
- Bogenberger, J.M.; DeLeon, T.T.; Arora, M.; Ahn, D.H.; Borad, M.J. Emerging role of precision medicine in biliary tract cancers. NPJ. Precis. Oncol. 2018, 2, 21. [Google Scholar] [CrossRef][Green Version]
- Hanker, A.B.; Garrett, J.T.; Estrada, M.V.; Moore, P.D.; Ericsson, P.G.; Koch, J.P.; Langley, E.; Singh, S.; Kim, P.S.; Frampton, G.M.; et al. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin. Cancer Res. 2017, 23, 4323–4334. [Google Scholar] [CrossRef][Green Version]
- Rizzo, A.; Ricci, A.D.; Brandi, G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res. Commun. 2021, 27, 100337. [Google Scholar] [CrossRef]
- Harding, J.J.; Piha-Paul, S.A.; Shah, R.H.; Cleary, J.M.; Quinn, D.I.; Brana, I.; Moreno, V.; Borad, M.J.; Loi, S.; Spanggaard, I.; et al. Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. J. Clin. Oncol. 2022, 40 (Suppl. 16), 4079. [Google Scholar] [CrossRef]
- Li, B.T.; Smit, E.F.; Goto, Y.; Nakagawa, K.; Udagawa, H.; Mazières, J.; Nagasaka, M.; Bazhenova, L.; Saltos, A.N.; Felip, E.; et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2022, 386, 241–251. [Google Scholar] [CrossRef] [PubMed]
- Weisser, N.E.; Wickman, G.; Abraham, L.; O’Toole, J.; Harbourne, B.; Guedia, J.; Cheng, C.W.; Chan, P.; Browman, D.; Gold, M.R.; et al. Abstract 1005: The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers. Cancer Res. 2021, 81, 1005. [Google Scholar] [CrossRef]
- Meric-Bernstam, F.; Beeram, M.; Hamilton, E.; Oh, D.-Y.; Hanna, D.L.; Kang, Y.-K.; Elimova, E.; Chaves, J.; Goodwin, R.; Lee, J.; et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study. Lancet Oncol. 2022, 23, 1558–1570. [Google Scholar] [CrossRef]
- Javle, M.; Borad, M.J.; Azad, N.S.; Kurzrock, R.; Abou-Alfa, G.K.; George, B.; Hainsworth, J.; Meric-Bernstam, F.; Swanton, C.; Sweeney, C.J.; et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021, 22, 1290–1300. [Google Scholar] [CrossRef]
- Lee, C.K.; Chon, H.J.; Cheon, J.; Lee, M.A.; Im, H.-S.; Jang, J.-S.; Kim, M.H.; Park, S.; Kang, B.; Hong, M.; et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol. Hepatol. 2023, 8, 56–65. [Google Scholar] [CrossRef]
- Xu, Y.; Wang, Y.; Gong, J.; Zhang, X.; Peng, Z.; Sheng, X.; Mao, C.; Fan, Q.; Bai, Y.; Ba, Y.; et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021, 24, 913–925. [Google Scholar] [CrossRef]
- Yu, J.; Fang, T.; Yun, C.; Liu, X.; Cai, X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front. Mol. Biosci. 2022, 9, 847835. [Google Scholar] [CrossRef] [PubMed]
- Ohba, A.; Morizane, C.; Kawamoto, Y.; Komatsu, Y.; Ueno, M.; Kobayashi, S.; Ikeda, M.; Sasaki, M.; Furuse, J.; Okano, N.; et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). J. Clin. Oncol. 2022, 40, 4006. [Google Scholar] [CrossRef]
- Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.T.; Prat, A.; Chae, Y.S.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 2022, 387, 9–20. [Google Scholar] [CrossRef]
- Peck, J.; Wei, L.; Zalupski, M.; O’Neil, B.; Calero, M.V.; Bekaii-Saab, T. HER2/neu may not be an interesting target in biliary cancers: Results of an early phase II study with lapatinib. Oncology 2012, 82, 175–179. [Google Scholar] [CrossRef] [PubMed]
- Ramanathan, R.K.; Belani, C.; Singh, D.A.; Tanaka, M.; Lenz, H.-J.; Yen, Y.; Kindler, H.L.; Iqbal, S.; Longmate, J.; Mack, P.C.; et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 2009, 64, 777–783. [Google Scholar] [CrossRef] [PubMed]
- Pignochino, Y.; Sarotto, I.; Peraldo-Neia, C.; Penachioni, J.Y.; Cavalloni, G.; Migliardi, G.; Casorzo, L.; Chiorino, G.; Risio, M.; Bardelli, A.; et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010, 10, 631. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Bai, Z.; Guo, Z.; Liu, J.; Chen, Y.-A.; Lu, Q.; Zhang, P.; Hong, L.; Wang, Y.; Dong, J. Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1-Mediated Gemcitabine Chemoresistance. Front. Oncol. 2022, 12, 860339. [Google Scholar] [CrossRef]
- Chakrabarti, S.; Kamgar, M.; Mahipal, A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers 2020, 12, 2039. [Google Scholar] [CrossRef]
Primary Tumor Site | Frequency of HER2 Alteration |
---|---|
Intrahepatic cholangiocarcinoma | 5.8% |
Extrahepatic cholangiocarcinoma | 13.9% |
Gallbladder cancer | 36.4% |
Ampulla of Vater | 18.2% |
Type of HER2 Alteration | Frequency of HER2 Alteration 100% (n = 18) |
---|---|
Point mutation | 27.8% (n = 5) |
Gene amplification | 61.1% (n = 11) |
Point mutation and gene amplification | 11.1% (n = 2) |
Primary Tumor Site | Frequency of HER2 Alteration | Type of HER2 Alteration |
---|---|---|
Intrahepatic CCA | 4.2% | Point mutation (23.8%) and copy number alteration (66.6%) |
Extrahepatic CCA | 9.7% | Point mutation (53.6%) and copy number alteration (41.2%) |
Clinical Trial | Drug | Patient Characteristics | Study Phase | Recruitment Status | Primary Endpoint | Results |
---|---|---|---|---|---|---|
NCT00478140 | Trastuzumab | Previously treated, locally advanced or metastatic gallbladder cancer or bile duct cancer that cannot be removed by surgery | II | Terminated due to slow accrual | ORR, DOR | Terminated |
NCT00107536 | Lapatinib ditosylate | Previously treated, unresectable liver or biliary tract cancer (BTC) | II | Completed | ORR, PFS, AEs, median OS, OS | Completed |
NCT04466891 (HERIZON-BTC-01) | Zanidatamab | Previously treated, advanced or metastatic HER2-amplified BTCs | II | Active, not recruiting | ORR, DOR, DCR, PFS, OS, AEs | Not recruiting |
NCT04329429 | RC48-ADC | Previously treated, locally advanced or metastatic HER2 overexpressed BTC who have failed first-line chemotherapy | II | Recruiting | ORR, DOR, PFS, OS, DCR, AEs | Active |
NCT03929666 | ZW25 (Zanidatamab) Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | Previously treated, unresectable, locally advanced, recurrent, or metastatic HER2-expressing BTC | II | Recruiting | DLT, AEs, ORR | Active |
NCT04837508 | MRG002 ADC | Previously treated, unresectable locally advanced or metastatic BTC patients who have progressed during or relapsed after at least one prior stand therapy | II | Recruiting | ORR | Active |
NCT04722133 | Herzuma (Trastuzumab-pkrb) mFOLFOX | Previously treated, HER2-positive advanced/metastatic/nonresectable BTC | II | Recruiting | ORR, PFS, DCR, OS, AEs | Active |
NCT05417230 | RC48-ADC Envafolimab (anti-PDL1) | Previously treated, locally advanced or metastatic BTC with positive HER-2 | II | Not yet recruiting | ORR, PFS, DCR, OS, AEs | Active |
NCT04482309 (DESTINY-PanTumor02) | Trastuzumab Deruxtecan (T-DXd, DS-8201a) | HER2-overexpressing tumor-specific cohorts including BTC | II | Active, not recruiting | ORR, PFS, DCR, OS, AEs | Active, not recruiting |
NCT05540483 (RIGHT) | RC-48 GLS-010 (anti-PD1) | Previously treated unresectable BTC | II | Recruiting | ORR, AEs, PFS, DOR, DCR, OS | Active |
NCT04450732 | GQ1001 | Previously treated, HER2-positive advanced solid tumors | I | Recruiting | DLT, AEs, maximum tolerated dose (MTD) | Active |
NCT02451553 | Afatinib dimaleate Capecitabine | Previously treated, advanced refractory solid tumors, pancreatic cancer, or biliary cancer | I | Completed | DLT, AEs, MTD | Completed |
NCT04660929 | CT-0508 (CAR macrophages) | Previously treated, HER2-overexpressing solid tumors | I | Recruiting | AEs, ORR, PFS | Active |
NCT04579380 | Tucatinib Trastuzumab | Previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations | II | Recruiting | cORR, DCR, PFS, OS, AEs | Active |
NCT04278144 | BDC-1001 (immune stimulating antibody conjugate, ISAC) Nivolumab | HER2-overexpressing advanced malignancies | I/II | Recruiting | AEs, DLT, ORR, DOR, DCR, PFS | Active |
NCT04460456 | SBT6050 (ISAC) Pembrolizumab Cemiplimab | HER2 expressing or amplified advanced malignancies | I | Active, not recruiting | DLT, AEs, ORR, DOR, DCR, PFS | Active, not recruiting |
NCT05150691 | DB-1303 | HER2 expressing advanced solid tumors | I/II | Recruiting | DLT, ORR, AEs | Active |
NCT00478140 | Trastuzumab | HER2/neu-positive advanced gallbladder or biliary tract cancer | II | Terminated (Due to slow accrual) | ORR, DCR, OS | Terminated |
NCT02999672 | Trastuzumab emtansine | HER2 overexpressing solid tumors | II | Completed | OS, PFS, AEs | Completed |
NCT04430738 | Tucatinib Trastuzumab FOLFOX CAPOX Pembrolizumab | HER2+ gastrointestinal cancers | I/II | Recruiting | DLT, AEs, ORR, DOR, PFS, OS | Active |
NCT03613168 (BILHER) | Trastuzumab GEMCIS | HER2+ biliary tract cancer | II | Completed | RR, PFS, OS | Completed |
NCT00101036 | Lapatinib ditosylate | Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | II | Completed | ORR, OS, PFS | Completed |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ayasun, R.; Ozer, M.; Sahin, I. The Role of HER2 Status in the Biliary Tract Cancers. Cancers 2023, 15, 2628. https://doi.org/10.3390/cancers15092628
Ayasun R, Ozer M, Sahin I. The Role of HER2 Status in the Biliary Tract Cancers. Cancers. 2023; 15(9):2628. https://doi.org/10.3390/cancers15092628
Chicago/Turabian StyleAyasun, Ruveyda, Muhammet Ozer, and Ilyas Sahin. 2023. "The Role of HER2 Status in the Biliary Tract Cancers" Cancers 15, no. 9: 2628. https://doi.org/10.3390/cancers15092628
APA StyleAyasun, R., Ozer, M., & Sahin, I. (2023). The Role of HER2 Status in the Biliary Tract Cancers. Cancers, 15(9), 2628. https://doi.org/10.3390/cancers15092628